Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

BACKGROUND: cKIT kinase overexpression and gain-of-function mutations are the critical pathogenesis of gastrointestinal stromal tumors (GISTs). Although the multiple kinase inhibitors such as imatinib, sunitinib, and regorafenib have been approved for GISTs, the acquisition of polyclonal secondary r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Liu, Feiyang, Zou, Fengming, Chen, Cheng, Yu, Kailin, Liu, Xiaochuan, Qi, Shuang, Wu, Jiaxin, Hu, Chen, Hu, Zhenquan, Liu, Juan, Liu, Xuesong, Wang, Li, Ge, Juan, Wang, Wenchao, Ren, Tao, Bai, Mingfeng, Cai, Yujiao, Xiao, Xudong, Qian, Feng, Tang, Jun, Liu, Qingsong, Liu, Jing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535728/
https://ncbi.nlm.nih.gov/pubmed/31205508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919849757
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak